The tentative deal comes months after CVS Health reached a proposed settlement in the lawsuit alleging major pharmacy benefit managers are inflating insulin costs.

The investigation by Florida’s attorney general comes as states look to check pharmacy benefit managers for allegedly driving ...

Roughly a third of American adults report difficulty paying for prescription drugs, and many are forced to skip doses, delay ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a win for GLP-1 patients.

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered medications last year, drugmaker Eli Lilly said.

While PBM reforms that passed earlier this year will spur further changes in the way business is conducted, it’s anti-trust legislation that could have the most impact.

The expanded TrumpRx platform offers more discounts, but lower drug costs aren’t guaranteed.

The best discoveries in life happen when you’re not looking for them, like finding twenty bucks in your jacket pocket or ...

By Amina Niasse and Sriparna Roy June 12 (Reuters) - Cigna's pharmacy benefits services unit Express Scripts requested on ...

Express Scripts and the PBM lobby are following in CVS Caremark’s footsteps in filing complaints challenging the FAIR Rx Act, ...